Drug Pipeline

NKX019 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
2
Recruiting
1
Top Sponsors
3
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-27 NCT06733935
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)		 Enrollment increased: 144 -> 240 participants
2026-05-23 NCT06557265
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)		 Primary endpoint(s) modified
2026-05-23 NCT06557265
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)		 Enrollment increased: 96 -> 120 participants
Active Studies by Phase
Phase 1/2
2
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT06557265 A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) Lupus Nephritis Recruiting
NCT06733935 A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) Systemic Sclerosis Recruiting
Phase 1
NCT05020678 NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK)… Lymphoma, Non-Hodgkin Active, Not Recruiting
Sponsors Running NKX019 Trials
Nkarta, Inc. (3)
Disease Areas
Leukemia (1) Acute Lymphoblastic Leukemia (ALL) (1) Chronic Lymphocytic Leukemia (CLL) (1) Mantle Cell Lymphoma (1) Lupus (SLE) (1) Rheumatoid Arthritis (1) Scleroderma (1)
Get alerts when NKX019 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free